Ibuprofen Market Research, 2033
The global ibuprofen market size was valued at $100.0 million in 2023, and is projected to reach $213.6 million by 2033, growing at a CAGR of 7.9% from 2024 to 2033. The ibuprofen market is driven by several key factors, including the rising prevalence of chronic diseases such as arthritis and cardiovascular conditions, which increase the demand for pain management solutions. Additionally, the growing awareness of over-the-counter (OTC) pain relief medications and their accessibility contributes to market expansion.
Market Introduction and Definition
Ibuprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID) renowned for its effectiveness in alleviating pain, reducing inflammation, and lowering fever. It belongs to the class of medications known as analgesics, which are commonly used to relieve mild to moderate pain, such as headaches, toothaches, muscle aches, menstrual cramps, and arthritis. Ibuprofen works by inhibiting the production of prostaglandins, substances in the body that contribute to pain and inflammation. Available over-the-counter and in prescription strengths, ibuprofen offers versatility in its use, catering to various pain management needs. Its popularity stems from its efficacy, rapid onset of action, and relatively few side effects when used appropriately. However, prolonged or excessive use of ibuprofen can lead to gastrointestinal complications, such as ulcers and gastrointestinal bleeding, as well as adverse effects on kidney function and cardiovascular health. Therefore, it is essential to use ibuprofen as directed and under medical supervision, especially for individuals with preexisting medical conditions or those taking other medications. Despite these considerations, ibuprofen remains a cornerstone in pain relief and fever management, serving millions worldwide as a trusted remedy for everyday discomfort.
Key Takeaways
- The ibuprofen market share study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period.
- More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major Ibuprofen industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions to achieve their most ambitious growth objectives
Key Market Dynamics
Key factors driving the ibuprofen market growth include high adoption of ibuprofen for pain management and rise in prevalence of arthritis. The high adoption of ibuprofen for pain management stands as a major driver propelling the growth of the Ibuprofen market. Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) , is widely recognized for its efficacy in alleviating pain and inflammation associated with various conditions ranging from headaches and muscle aches to arthritis and menstrual cramps. Its effectiveness in providing relief from mild to moderate pain has led to its widespread adoption among healthcare professionals and consumers alike. Individuals seeking symptomatic relief from common ailments often turn to ibuprofen due to its accessibility as an over-the-counter medication and its reputation for delivering quick and reliable pain relief. According to the 2023 report by the National Library of Medicine, Ibuprofen was reported to FDA-approved for use in mild to moderate pain. Moreover, ibuprofen's versatility in addressing a wide spectrum of pain conditions, combined with its relatively favorable safety profile when used as directed, further contributes to its popularity as a go-to analgesic. Thus, the rise in adoption of the ibuprofen as effective pain management solution is expected to drive the ibuprofen market size.
In addition, according to ibuprofen market forecast analysis the rise in the prevalence of arthritis serves as a significant driver propelling the growth of the Ibuprofen market. Arthritis, a chronic condition characterized by inflammation and stiffness in the joints, affects millions of individuals worldwide, with the prevalence increasing steadily due to factors such as aging populations, sedentary lifestyles, and obesity. In a report by the Center of Disease Control and Prevention, it was reported that 47.3% of adults were diagnosed with arthritis.The demand for ibuprofen is expected to surge as the prevalence of arthritis continues to escalate globally. Thus, the rise in the prevalence of the arthritis is expected to contribute significantly in the growth of ibuprofen industry.
Market Segmentation
The Ibuprofen market is segmented into type, application, distribution channel, and region. By type, the market is divided into tablet, capsule, syrup, injection, and others. By application, the market is classified into rheumatoid arthritis and osteoarthritis, cancer, pain/fever/dysmenorrhea, inflammatory diseases, headache, and others. By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional Market Outlook
North America is expected to dominate ibuprofen market share in 2023, this is attributed to rise in prevalence of chronic pain conditions such as arthritis, back pain, and headaches is notably high in North America, driven partly by an aging population and lifestyle factors such as sedentary behavior and obesity. As a result, there is a consistent demand for effective pain relief medications like Ibuprofen, which is widely recognized for its efficacy in managing mild to moderate pain and inflammation. Secondly, the widespread availability and accessibility of Ibuprofen as an over-the-counter (OTC) medication contributes to its popularity among consumers seeking convenient and immediate pain relief. The OTC status of Ibuprofen eliminates the need for a prescription, making it easily accessible in pharmacies, grocery stores, and online platforms, thus driving consumer adoption and sales volume.
Additionally, North America boasts a robust healthcare infrastructure and pharmaceutical industry, with a strong network of healthcare providers, pharmacies, and distribution channels facilitating the widespread availability and promotion of Ibuprofen products. Moreover, according to ibuprofen market opportunity analysis Asia-Pacific is expected to register fastest growth owing to growing population, urbanization, and rising healthcare expenditures, driving greater awareness and accessibility to healthcare services and medications.
- An article published by Versus Arthritis (UK’s largest charity dedicated to supporting people with arthritis) , reported that 10 million people in the UK have osteoarthritis.
- In an article published by Center of Disease Control and Prevention, it was reported that in 2021 there were around 5.3 million arthritis patients in the U.S.
- In an article published by Center of Disease Control and Prevention, it was reported that the adoption of ibuprofen to treat menstrual cramps is 6.2%.
Industry Trends
- In March 2021, Abbott launched a new Brufen Power spray advertising campaign starring actor Tiger Shroff. The ad film emphasizes the advantages of the new spray’s double-strength formulation, which is delivered with a one-shot spray that ensures only the necessary amount is sprayed on.
- In August 2021, Alkem Laboratories announced the launch of Ibuprofen and Famotidine tablets in the U.S. market which are used to treat the symptoms of rheumatoid arthritis and osteoarthritis.
- According to the National Library of Medicine, Ibuprofen is indicated and FDA-approved for use in the treatment of inflammatory diseases and rheumatoid disorders
Arthritis Patient Populations
Arthritis is a prevalent chronic condition affecting patient populations across different regions; however, the prevalence of arthritis varies in different regions depending upon demographics of the region. In developed regions such as North America and Europe, the aging population is a significant driver of arthritis prevalence. As individuals age, the likelihood of developing arthritis, particularly osteoarthritis, increases, leading to a substantial proportion of arthritis patients in these regions being older adults. Moreover, lifestyle factors such as obesity, sedentary behavior, and occupational hazards contribute to the burden of arthritis, with a notable prevalence among middle-aged and elderly individuals. In contrast, emerging economies in Asia-Pacific, Latin America, and the Middle East and Africa (MEA) also experience a significant burden of arthritis, albeit with some distinctions. In these regions, the prevalence of arthritis is not only influenced by aging populations but also by factors such as rapid urbanization, changing dietary habits, and genetic predispositions. In addition, access to healthcare resources and arthritis treatments may vary, with disparities in diagnosis, management, and access to care among different socioeconomic groups.
Competitive Landscape
The major players operating in the Ibuprofen Market include Pfizer Inc., Abbott Laboratories Ltd., Solara Active Pharma Sciences Ltd., ?h?nd?ng ??nhu? ?h?rm???ut???l ??.Ltd, ??L ?h?m???l? and ?h?rm???ut???l L?m?t?d, ?ub?? ?????u?? ?h?rm???ut???l ??.Ltd, ?tr?d?? ?h?rm? ????n?? L?m?t?d (?h??un ?h?rm???ut???l? L?m?t?d) , ??rr?g? ??m??n? ?l?, BASF SE, and Biocause Inc. Other players operating in Ibuprofen Market include ??ll?n?kr?dt ?l?., Designs For Vision, Neitz Instruments Co. Ltd., and PeriOptix.
Recent Key Strategies and Developments
- In August 2023, Solara Active Pharma Sciences, announced the inauguration of its new ibuprofen API manufacturing facility in Spain. This expansion is expected to double Solara’s ibuprofen API production, catering to the increasing demand for this widely used pain reliever.
- In July 2023, BASF SE and Recipharm, announced collaboration to pioneer the development of innovative ibuprofen formulations. Leveraging BASF’s expertise in ibuprofen synthesis and Recipharm’s proficiency in drug formulation, the partnership aims to create formulations that are more effective, exhibit fewer side effects, and are easier to administer.
- In June 2023, Glenmark Pharmaceuticals launched a new ibuprofen-based topical gel designed for fast and efficient relief from minor aches and pains. The over-the-counter availability of this gel without a prescription adds a convenient option for individuals seeking immediate pain relief.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ibuprofen market analysis from 2024 to 2033 to identify the prevailing ibuprofen market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the ibuprofen market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global ibuprofen market trends, key players, market segments, application areas, and market growth strategies.
Key Sources Referred
- Versus Arthritis
- World Health Organization
- Ministry of Health, India
- Center of Disease Control and Prevention.
- National Library of Medicine
- American Orthopaedic Association
- American Academy of Orthopaedic Surgeons
Ibuprofen Market Report Highlights
Aspects | Details |
Market Size By 2033 | USD 213.6 Million |
Growth Rate | CAGR of 7.9% |
Forecast period | 2024 - 2033 |
Report Pages | 280 |
By Type |
|
By Application |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | Abbott Laboratories, Hubei Biocause Pharmaceutical Co Ltd, Biocause Inc, Shandong Xinhua Pharmaceutical Co Ltd, BASF SE, IOL Chemicals and Pharmaceutical Ltd, Pfizer Inc., Strides Pharma Science Ltd, Perrigo Company Plc, Solara Active Pharma Sciences Ltd |
Analyst Review
The global ibuprofen market is currently experiencing a period of significant growth, driven by rising demand for pain management solutions and the increasing prevalence of chronic diseases. As a widely used nonsteroidal anti-inflammatory drug (NSAID), ibuprofen's application spans across various conditions including arthritis, dental pain, headaches, and menstrual cramps, contributing to its robust market demand. North America dominated the market share in 2023, owing to the high adoption of the ibuprofen as nonsteroidal anti-inflammatory drug, well developed healthcare infrastructure and rise in prevalence of the arthritis and surge in geriatric population.
The global ibuprofen market is projected to reach $213.6 million by 2033
The forecast period for Ibuprofen market is 2024-2033.
The global ibuprofen market size was valued at $100.0 million in 2023
The base year is 2023 in Ibuprofen market
Major key players that operate in the Ibuprofen market are Pfizer Inc., Abbott Laboratories Ltd., Solara Active Pharma Sciences Ltd., ?h?nd?ng ??nhu? ?h?rm???ut???l ??.Ltd,
Loading Table Of Content...